UBS Reiterates Buy on AbbVie (ABBV) Following Conference Call

Pre-Open Stock Movers 11/02: (HTCH) (DYAX) (CTCT) Higher; (CMG) (CL) (V) Lower (more...)

November 2, 2015 9:28 AM EST

Hutchinson Technology (Nasdaq: HTCH) 104% HIGHER; TDK Corporation and Hutchinson Technology Incorporated (Nasdaq: HTCH) jointly announced that they have entered into a definitive merger agreement under which TDK will acquire all of the outstanding shares of common stock of HTI for base consideration of US$3.62 per share, plus additional consideration of up to US$0.38 per share, depending on the level of cash (subject to certain adjustments) less any outstanding borrowings on HTI's revolving line of credit ("net cash") held by HTI as of... More

Morgan Stanley Upgrades Abbvie (ABBV) to Overweight

November 2, 2015 9:26 AM EST

Morgan Stanley upgraded Abbvie (NYSE: ABBV) from Equalweight to Overweight with a price target of $73.00.

For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.

Shares of Abbvie closed at $59.55 yesterday.

... More

Abbvie (ABBV) Added to Conviction Buy List at Goldman Sachs; Analyst Sees 34% Upside

November 2, 2015 8:37 AM EST

Goldman Sachs upgraded Abbvie (NYSE: ABBV) from Buy to Conviction Buy with a price target of $80.00 (from $76.00), suggesting upside of 34%. Analyst Jami Rubin called Abbvie "one of the most dislocated names in pharma," and he thinks the gap between management expectations and Street expectations will start closing.

"We have long stated that our confidence in ABBV is based on 1) stability and growth of Humira based on a multi-pronged defense... More

Wall St. climbs, led by energy, healthcare; Nasdaq 100 hits 15-year high

November 2, 2015 7:23 AM EST

By Lewis Krauskopf

(Reuters) - U.S. stocks added to their recent run with gains across all sectors on Monday, led by increases in the beaten-down energy group and the acquisition-driven healthcare industry.

The gains on the first trading day of the month followed the best monthly performance of the major indexes in four years in October. The Nasdaq 100 on Monday closed at its highest level in more than 15 years.

Data on Monday showed U.S. manufacturing activity in October sank to a 2-1/2-year low, but a rise in new orders offered encouragement. Elsewhere,... More

AbbVie (ABBV) Reports Strong 3Q and Long term outlook; Cowen Reiterates Outperform

October 30, 2015 1:23 PM EDT

Cowen reiterated an Outperform rating and $77.00 price target on Abbvie (NYSE: ABBV) following the company's 3Q earnings results. Q3 EPS of $1.13 was $0.06 above consensus. Full year guidance has been raised to $4.26-4.28 (prior $4.10-4.30). Q3 sales of $5,944MM (+18%) were $54MM above... More

Stocks slip but post best month in four years

October 30, 2015 7:32 AM EDT

By Lewis Krauskopf

(Reuters) - U.S. stock indexes finished with their strongest monthly performances in four years on Friday, even as they dipped for the day amid a mixed bag of earnings reports.

For October, all three major indexes posted their biggest percentage increases since October 2011, with the S&P 500 rising 8.3 percent, led by energy and materials, while a measure of volatility fell.

On Friday, CVS Health (NYSE: CVS) fell 4.8 percent to $98.78 after a disappointing profit forecast for 2016.

The S&P 500 energy index was the best performing sector, rising... More

AbbVie (ABBV) Raises Quarterly Dividend 11.8% to $0.57; 4.2% Yield

October 30, 2015 6:57 AM EDT

AbbVie (NYSE: ABBV) declared a quarterly dividend of $0.57 per share, or $2.28 annualized. This is an 11.8% increase from the prior dividend of $0.51.

The dividend will be payable on February 16, 2016, to stockholders of record on January 15, 2016, with an ex-dividend date of January 13,... More

AbbVie (ABBV) Tops Q3 EPS by 7c; Guides FY15 EPS Above Views

October 30, 2015 6:56 AM EDT

AbbVie (NYSE: ABBV) reported Q3 EPS of $1.13, $0.07 better than the analyst estimate of $1.06. Revenue for the quarter came in at $4.94 billion versus the consensus estimate of $5.9 billion.

Third-quarter sales growth was driven by the continued strength of HUMIRA and other promoted... More

AbbVie (ABBV) Issues Long-Term Outlook; Boosts Qtr. Dividend

October 30, 2015 6:55 AM EDT

AbbVie (NYSE: ABBV) outlined the company's long-term strategic and financial objectives, including expectations for growth and other financial metrics over its long-range plan, through 2020.

"AbbVie is well-positioned to deliver strong top- and bottom-line performance through 2020 and beyond," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We have built a strong foundation, establishing growth platforms in some of the largest and most attractive market segments. And, we have a robust and compelling pipeline which will contribute significantly to our performance over our long-range-plan."

Based on continued strong performance from its existing... More

Trading Radar for 10/30: ExxonMobil (XOM), Seagate (STX), Newell Rubbermaid (NWL), Wayfair (W) Report

October 29, 2015 2:16 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Personal Spending - Street sees 0.2%Personal Income - Street sees (0.1%)PCE Prices: Core - Street sees 0.1%Employment Cost Index - Street sees 0.5%

Earnings:

Aaron's (NYSE: AAN) - consensus EPS $0.48
AbbVie (NYSE: ABBV) - consensus EPS $1.06
ArcBest (Nasdaq: ARCB) - consensus EPS $0.82
BankFinancial (Nasdaq:... More